The effect of short-term dutasteride intake in early-stage prostate cancer: analysis of 148 patients who underwent three-dimensional prostate mapping biopsy.

Abstract

OBJECTIVES:

The effect of dutasteride on existing prostate cancer volume is largely unknown. In this study, we assessed the impact of dutasteride on tumor burden and Gleason score.

METHODS:

A retrospective review of patients from our institution was performed, examining men interested in surveillance for prostate cancer, who underwent transperineal three-dimensional mapping (TP-3DM) biopsy within 3-6 months after their initial cancer diagnosis. The criteria to qualify for TP-3DM biopsy included prostate-specific antigen < 10 ng/mL, Gleason score ≤ 7, ≤ 2 positive cores out of 12. There were 2 cohorts of men--those who took dutasteride daily before the TP-3DM biopsy and those who did not receive any 5ARIs. Upstaging of prostate cancer diagnosis was defined as an increase in one or more positive cores or a change from unilateral to bilateral disease.

RESULTS:

From 2006-2008, a cohort of 148 men underwent TP-3DM biopsy of the prostate. Ninety-one men received a treatment regime of dutasteride at least 3 months before TP-3DM biopsy. Fifty-seven men did not receive dutasteride or any other 5ARI. Approximately 74% of men who did not take dutasteride were upstaged and/or upgraded compared with 49.4% of men who received dutasteride (P = .0038).

CONCLUSIONS:

We observed a 24.3% decrease in the proportion of upstaging and/or upgrading of prostate cancer in men who received dutasteride at least 3 months before 3D prostate TP-3DM biopsy. Thus, the effect of dutasteride on prostate cancer may have implications for its potential use as a secondary chemoprevention agent.

• Authors: Al B Barqawi, Colin I O'Donnell, Vassilis J Siomos, Amy H Hou
• Journal: Urology (Urology) Vol. 76 Issue 5 Pg. 1067-71 (Nov 2010) ISSN: 1527-9995 [Electronic] United States
• PMID: 20472268 (Publication Type: Journal Article)
• Copyright: Copyright © 2010 Elsevier Inc. All rights reserved.

Chemical References

• 5-alpha Reductase Inhibitors
• Azasteroids
• Dutasteride

Topics

• 5-alpha Reductase Inhibitors (administration & dosage)
• Azasteroids (administration & dosage)
• Biopsy, Needle
• Chemoprevention
• Dutasteride
• Humans
• Male
• Prostatic Hyperplasia (drug therapy)
• Prostatic Neoplasms (pathology, prevention & control)
• Tertiary Prevention
• Ultrasonography, Interventional